LY-306740

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477241234 | IUPAC_name = (1R,2S)-2-[[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperazin-1-yl]methyl]cyclohexan-1-ol | image = LY-306740_structure.png | width = 200 | CAS_number = 161611-19-4 | PubChem = 3083545 | ChemSpiderID = 2340980 | UNII = 3X7Q2F3K0F | KEGG = D08495 | ChEMBL = 2103870 | C=18 | H=28 | N=2 | O=3 | smiles = C1CC[C@H]([C@@H](C1)N2CCN(CC2)CC3=C4C=CC(O3)=CO4)O }}

LY-306740 is a chemical compound that has been studied for its potential effects on the central nervous system. It is primarily known as a selective antagonist of the 5-HT1A receptor, a subtype of the serotonin receptor. This compound was developed by the pharmaceutical company Eli Lilly and Company.

Pharmacology

LY-306740 acts as a selective antagonist at the 5-HT1A receptor, which is a G protein-coupled receptor (GPCR) involved in the modulation of neurotransmission. The 5-HT1A receptor is implicated in various physiological processes, including mood regulation, anxiety, and cognition. By blocking this receptor, LY-306740 may alter serotonin signaling, which could have therapeutic implications for disorders such as depression and anxiety disorders.

Research and Development

The development of LY-306740 was part of a broader effort to explore the therapeutic potential of 5-HT1A receptor antagonists. Preclinical studies have shown that LY-306740 can influence behavioral and neurochemical responses in animal models, suggesting potential applications in treating psychiatric conditions. However, as of the latest updates, LY-306740 has not been approved for clinical use, and further research is needed to fully understand its efficacy and safety profile.

Mechanism of Action

LY-306740 binds to the 5-HT1A receptor and prevents the binding of serotonin, the natural ligand. This antagonistic action can lead to increased levels of serotonin in the synaptic cleft, as the autoreceptor-mediated feedback inhibition is reduced. The precise effects of this mechanism depend on the specific neural circuits involved and the overall serotonergic tone in the brain.

Potential Applications

While LY-306740 has not been approved for any specific medical use, its pharmacological profile suggests potential applications in:

• Major depressive disorder
• Generalized anxiety disorder
• Obsessive-compulsive disorder

Safety and Side Effects

As LY-306740 has not undergone extensive clinical trials, its safety and side effect profile are not well-documented. However, as with other 5-HT1A receptor antagonists, potential side effects could include nausea, dizziness, and changes in mood or behavior.

Also see

• 5-HT1A receptor
• Serotonin receptor
• Antidepressant
• Anxiolytic